Treatment of HBeAg-Positive Hepatitis B with Peginterferon and Lamivudine

To the Editor: Lau et al. (June 30 issue) 1 studied pegylated interferon for the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. Overall, HBeAg seroconversion was highest among patients treated with pegylated interferon monotherapy, despite the more potent hepatitis B virus (HBV) DNA suppression with lamivudine at 48 weeks. Although viral suppression and HBeAg seroconversion are well correlated, 2 the degree of viral suppression needed for seroconversion to occur is not well defined. With regard to this study, it would be of interest to know what the degree of HBV DNA suppression was among patients in whom HBeAg or . . .